Aging rather than aneuploidy affects monoamine neurotransmitters in brain regions of Down syndrome mouse models by Dekker, AD et al.
Accepted Manuscript
Aging rather than aneuploidy affects monoamine
neurotransmitters in brain regions of Down syndrome mouse
models
Alain D. Dekker, Yannick Vermeiren, Christelle Albac, Eva Lana-
Elola, Sheona Watson-Scales, Dorota Gibbins, Tony Aerts, Debby
Van Dam, Elizabeth M.C. Fisher, Victor L.J. Tybulewicz, Marie-
Claude Potier, Peter P. De Deyn
PII: S0969-9961(17)30134-1
DOI: doi: 10.1016/j.nbd.2017.06.007
Reference: YNBDI 3977
To appear in: Neurobiology of Disease
Received date: 11 April 2017
Revised date: 2 June 2017
Accepted date: 12 June 2017
Please cite this article as: Alain D. Dekker, Yannick Vermeiren, Christelle Albac, Eva
Lana-Elola, Sheona Watson-Scales, Dorota Gibbins, Tony Aerts, Debby Van Dam,
Elizabeth M.C. Fisher, Victor L.J. Tybulewicz, Marie-Claude Potier, Peter P. De Deyn
, Aging rather than aneuploidy affects monoamine neurotransmitters in brain regions
of Down syndrome mouse models, Neurobiology of Disease (2017), doi: 10.1016/
j.nbd.2017.06.007
This is a PDF file of an unedited manuscript that has been accepted for publication. As
a service to our customers we are providing this early version of the manuscript. The
manuscript will undergo copyediting, typesetting, and review of the resulting proof before
it is published in its final form. Please note that during the production process errors may
be discovered which could affect the content, and all legal disclaimers that apply to the
journal pertain.
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
Title 
Aging rather than aneuploidy affects monoamine neurotransmitters in brain regions of Down syndrome mouse 
models 
 
Authors 
Alain D. Dekker
a,b,c
, Yannick Vermeiren
a,b
, Christelle Albac
c
, Eva Lana-Elola
d
, Sheona Watson-Scales
d
, Dorota Gibbins
d
, 
Tony Aerts
b
, Debby Van Dam
a,b
, Elizabeth M. C. Fisher
e
, Victor L. J. Tybulewicz
d,f
, Marie-Claude Potier
c
 and Peter P. De 
Deyn
a,b,* 
 
Affiliations 
a 
Department of Neurology and Alzheimer Research Center, University of Groningen, University Medical Center 
Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands 
b
 Laboratory of Neurochemistry and Behaviour, Institute Born-Bunge, University of Antwerp, Universiteitsplein 1, 2610 
Wilrijk, Antwerp, Belgium 
c
 Sorbonne Universités, UPMC Université Paris 06, INSERM, CNRS (U75, U1127, U7225) and Institut du Cerveau et de 
la Moelle Epinière (ICM), Boulevard de l’Hôpital, 75013 Paris, France 
d
 The Francis Crick Institute, Midland Road, London NW1 1AT, United Kingdom 
e
 Department of Neurodegenerative Disease, Institute of Neurology, University College London, Queen Square, 
London WC1N 3BG, United Kingdom  
f
 Department of Medicine, Imperial College London, Du Cane Road, London W12 0NN, United Kingdom 
 
* Corresponding author 
Name:  Prof. dr. Peter P. De Deyn 
Address: Department of Neurology and Alzheimer Research Center, University Medical Center Groningen 
(UMCG), Hanzeplein 1, 9713 GZ Groningen, The Netherlands 
Telephone:  +31503614650 
E-mail:   p.p.de.deyn@umcg.nl 
 
Abstract 
Altered concentrations of monoamine neurotransmitters and metabolites have been repeatedly found in people with 
Down syndrome (DS, trisomy 21). Because of the limited availability of human post-mortem tissue, DS mouse models 
are of great interest to study these changes and the underlying neurobiological mechanisms. Although previous 
studies have shown the potential of Ts65Dn mice – the most widely used mouse model of DS – to model 
noradrenergic changes, a comprehensive monoaminergic characterization in multiple brain regions has not been 
performed so far. Here, we used RP-HPLC with electrochemical detection to quantify (nor)adrenergic (NA, adrenaline 
and MHPG), dopaminergic (DA, HVA and DOPAC), and serotonergic compounds (tryptophan, 5-HT and 5-HIAA) in ten 
regionally dissected brain regions of Ts65Dn mice, as well as in Dp1Tyb mice – a novel DS mouse model. Comparing 
young adult aneuploid mice (2.5-5.5 months) with their euploid WT littermates did not reveal generalized 
monoaminergic dysregulation, indicating that the genetic overload in these mice barely affected the absolute 
concentrations at this age. Moreover, we studied the effect of aging in Ts65Dn mice: comparing aged animals (12-13 
months) with their younger counterparts revealed a large number of significant changes. In general, the 
(nor)adrenergic system appeared to be reduced, while serotonergic compounds were increased with aging. 
Dopaminergic alterations were less consistent. These overall patterns appeared to be relatively similar for Ts65Dn and 
WT mice, though more observed changes were regarded significant for WT mice. Similar human post-mortem studies 
are necessary to validate the monoaminergic construct validity of the Ts65Dn and Dp1Typ mouse models. 
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1. Introduction 
 
Down syndrome (DS), caused by an additional copy of chromosome 21 (HSA21), is the most common intellectual 
disability with a genetic origin affecting nearly six million people worldwide (Ballard et al., 2016). DS is generally 
characterized by behavioral alterations (Dekker et al., 2015b) and reduced cognitive capacities, in particular impaired 
verbal short-term memory, explicit long-term memory, morphosyntax and an average IQ of 45 (Lott and Dierssen, 
2010; Vicari et al., 2004). Moreover, people with DS are at an extremely high risk to develop dementia: 68-80% 
develop Alzheimer’s disease (AD) by the age of 65 years (Wiseman et al., 2015), compared to 11% in the general (non-
intellectually disabled) population of 65 years and older (Alzheimer’s Assocation, 2016). 
 Elucidating the underlying neurobiological mechanisms affecting behavior and cognition in DS would greatly 
contribute to understanding the pathophysiology, as well as facilitate development of novel disease-modifying 
strategies. Of particular interest in this population are monoamine neurotransmitters: noradrenaline (NA), adrenaline, 
dopamine (DA) and serotonin (5-HT) and their metabolites (summarized in Fig. 1). A series of neurochemical studies 
has shown significant alterations in one or more monoamines in various brain regions (Godridge et al., 1987; Reynolds 
and Godridge, 1985; Risser et al., 1997; Whittle et al., 2007; Yates et al., 1981), cerebrospinal fluid (CSF) (Kay et al., 
1987; Schapiro et al., 1987) and serum/plasma (Coppus et al., 2007; Dekker et al., 2015a) of DS individuals as 
compared to non-DS controls. 
Although monoaminergic alterations in CSF and serum/plasma likely reflect changes in the brain, direct 
analysis of brain tissue is warranted to understand central neurotransmission alterations. Indeed, we previously 
studied monoamines and metabolites in post-mortem brain regions of behaviorally characterized patients in the 
general population with (early-onset) AD (Vermeiren et al., 2016, 2015, 2014a, 2014b), frontotemporal dementia 
(Vermeiren et al., 2016) and dementia with Lewy bodies (Vermeiren et al., 2015). Surprisingly, despite the high risk for 
dementia in DS, only a few post-mortem studies dating back to the 1980s have investigated monoamines in DS. 
Unfortunately, post-mortem brain samples from clinically and pathologically well-documented DS individuals have 
been rarely included in biobanks around the world, severely limiting the possibilities for such research.  
Thus, valid mouse models of DS are of great interest to study the potential monoaminergic alterations related 
to trisomy 21. In addition to the differences between DS and non-DS controls, monoaminergic changes have been 
reported in DS mouse models, in particular noradrenergic alterations (Dierssen et al., 1997; Lockrow et al., 2011; 
Salehi et al., 2009). These findings have been primarily observed in Ts(17
16
)65Dn mice (Ts65Dn in short), the most 
widely used and best characterized DS model. HSA21 contains 233 protein-encoding genes: among those genes with a 
homologue in mice, the majority (~58%) is found on a large segment of mouse chromosome 16 (Mmu16), and to a 
lesser extent on shorter segments of Mmu10 and Mmu17 (Lana-Elola et al., 2016). Ts65Dn mice carry an additional 
mini-chromosome that is formed by the translocation of a duplicated segment of Mmu16 to a small part of Mmu17 
(Davisson et al., 1990), making them trisomic for approximately 50% of the genes homologous to HSA21, but also for 
60 non-homologous genes on Mmu17 (Duchon et al., 2011). 
Of profound interest is the significant loss of neurons in the locus coeruleus (LC), the key production site of 
NA in the pons, in Ts65Dn mice of 12 months of age but not in Ts65Dn mice at 4 months of age as compared to age-
matched euploid wildtype (WTTs65Dn) littermates (Fortress et al., 2015; Lockrow et al., 2011). Neurodegeneration with 
progressive aging was further demonstrated by the significant loss of axonal processes and shrinkage of the 
noradrenergic neurons between 4 and 12 months in Ts65Dn, but not in WTTs65Dn (Lockrow et al., 2011). Similarly, 
Salehi and colleagues found a reduced number of LC neurons in Ts65Dn mice at 6 months and 18 months of age, but 
not in those of 3 months of age, as compared to age-matched WTTs65Dn mice. Moreover, NA levels in the hippocampus 
were significantly lower in Ts65Dn than in WTTs65Dn at 18 months. Despite the pronounced LC degeneration, impaired 
NA-modulated contextual learning could be rescued in these mice after treatment with the noradrenergic prodrug L-
threo-3,4-dihydroxyphenylserine (L-DOPS) or the β1-adrenergic receptor partial agonist xamoterol (Salehi et al., 
2009). Restoration of impaired noradrenergic neurotransmission may thus serve as potential disease-modifying 
therapy in DS (Phillips et al., 2016).  
Despite a large number of studies using Ts65Dn mice, a comprehensive monoaminergic characterization of 
the brain of this mouse model has not been conducted so far. Therefore, this study aimed to investigate the potential 
of DS mouse models (construct validity) in modelling the monoaminergic changes in DS by (1) establishing the 
monoaminergic profile in ten regionally dissected brain regions of aneuploid Ts65Dn mice in comparison to their 
euploid WTTs65Dn littermates, and (2) studying the effect of aging in Ts65Dn and WTTs65Dn mice. Using an optimized 
reversed-phase high-performance liquid chromatography (RP-HPLC) set-up with electrochemical detection we 
detected and quantified (nor)adrenaline and the metabolite 3-methoxy-4-hydroxyphenylglycol (MHPG), DA with its 
metabolites homovanillic acid (HVA) and 3,4-dihydroxyphenylacetic acid (DOPAC), tryptophan, and 5-HT with its 
metabolite 5-hydroxyindoleacetic acid (5-HIAA) in each of these brain regions.  
Whereas Ts65Dn mice have proven very useful for studying various phenotypic features present in people 
with DS (Gardiner, 2015), the additional 60 genes from Mmu17 that are not homologous to HSA21 may complicate 
the interpretation of generated data (Duchon et al., 2011). Therefore, new mouse models have been developed that 
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are only trisomic for genes homologous to HSA21, such as the Dp(16)1Yey strain that is trisomic for the entire 
homologous segment on Mmu16 (Yu et al., 2010). Similar to Dp(16)1Yey, the Dp1Tyb mouse model has been 
generated to exclude the effect of the irrelevant Mmu17 genes triplicated in Ts65Dn. Using Cre/loxP-mediated 
recombination, Dp1Tyb mice were engineered with a triplication of Mmu16 genes from Lipi to Zbtb21 including 148 
protein-encoding Mmu16 genes (Lana-Elola et al., 2016). Given the debate on the non-homologous genes in Ts65Dn 
mice, we also performed a first exploratory analysis of the monoaminergic profile of this new Dp1Typ mouse model.  
 
 
2. Materials & Methods 
 
2.1. Animals 
As Ts65Dn is the most widely used DS mouse model, the aim of this project was to establish its monoaminergic profile 
and evaluate the effect of aging in this model. Since Ts65Dn are trisomic for 60 Mmu17 genes that are not 
homologous to HSA21, we also conducted a first (pilot) study with young Dp1Tyb mice, which resemble the human 
situation more closely from a genetic point of view. Given the time-intensive nature of this project, the availability of 
aged Ts65Dn mice and that the aforementioned studies in Ts65Dn implicated monoaminergic changes with aging, 
possibly resembling the changes in humans, we studied the effect of aging only in the Ts65Dn mouse model.  
 
Table 1: Overview of experimental groups 
 
Experimental groups Number of mice Age in days 
Ts65Dn-young 21 117 (91-174) 
WTTs65Dn-young 18 118.5 (110-174) 
Ts65Dn-aged 11 377 (354-399) 
WTTs65Dn-aged 10 382 (376-382) 
Dp1Tyb 9 82 (79-93) 
WTDp1Tyb 9 84 (79-93) 
 
Age in days is provided as median with the age range between brackets. 
 
2.1.1. Ts65Dn mice  
Male Ts65Dn (n=32) and euploid WTTs65Dn littermates (n=28) were bred, aged and sacrificed in the Institut du Cerveau 
et de la Moelle Epinière (ICM, Paris, France). To study the effect of aging, we considered two age ranges (Table 1): 
young adult animals (~3-5.5 months) and aged animals (~12-13 months). Since the original homozygous Ts65Dn mice 
suffer from blindness due to the recessive retinal degeneration 1 mutation Pde6b
rd1
, we used an alternative strain 
that is wild-type for Pde6b
rd1
 (The Jackson Laboratory, Bar Harbor, USA, stock number 005252), thus preventing 
retinal degeneration. The Ts65Dn colony was maintained by crossing trisomic Ts65Dn females (B6EiC3Sn.BLiA-
Ts(17
16
)65Dn/DnJ) to B6EiC3Sn.Bli males (The Jackson Laboratory, stock numbers 005252 and 003647, respectively).  
Mixed-genotype groups were housed under standard conditions with ad libitum food and water, constant room 
temperature and a 12h light/dark cycle. The experiments were compliant with the ethical standards and animal 
welfare regulations of the French Ministry of Agriculture and the EU Directive 2010/63/EU. MC Potier has the 
authorization for experiments on vertebrates (N°A-75-2138, Direction Départementale de la Protection des 
Populations de Paris, Service Protection et Santé Animales, Environnement).  
  
2.1.2. Dp1Tyb mice 
The engineering of the C57BL/6J.129P2-Dp(16Lipi-Zbtb21)1TybEmcf/Nimr (Dp1Tyb) strain is described in Lana-Elola et 
al. (2016). In this first exploratory analysis of this model, we used young male Dp1Tyb (n=9) mice and euploid WTDp1Tyb 
littermates (n=9) aged 2.5-3 months (Table 1). All mice had been backcrossed at least 5 generations onto the C57BL/6J 
background. The animals were bred, aged and sacrificed in the Francis Crick Institute (London, UK). Animals were 
housed in specific pathogen free conditions, with ad libitum food and water, constant room temperature and a 12h 
light/dark cycle. The characterization and breeding of Dp1Tyb mice was carried out under a Project License granted by 
the UK Home Office, and in accordance with the EU Directive 2010/63/EU. 
 
2.2. Sacrifice 
After intraperitoneal anesthesia with pentobarbital, mice were sacrificed by cervical dislocation and subsequently fully 
submersed in liquid nitrogen (3 minutes) to stop metabolization of monoamines. Mice were stored at -80°C and 
shipped on dry ice to the Laboratory of Neurochemistry and Behaviour in Antwerp for further processing.  
 
2.3. Regional brain dissection 
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Brains were extracted from the frozen mice using surgical tools, and subsequently micro-dissected on a cold plate 
under a binocular microscope, resembling a previously published protocol (Van Dam et al., 2005). Per mouse, ten 
(sub)cortical brain regions were obtained: frontal cortex, temporal cortex, parietal cortex, occipital cortex, 
hippocampus, striatum, (hypo)thalamus, brainstem, cerebellum and olfactory bulb. The weight of the brain samples 
was determined in pre-weighted Eppendorf tubes. Samples were kept at -80°C until RP-HPLC analyses. 
 
2.4. Sample preparation 
Brain samples were defrosted to 4°C and subsequently homogenized in 800 µl sample buffer (50 mM citric acid, 50 
mM phosphoric acid, 0.1 mM EDTA, 8 mM KCl and 1.8 mM octane-1-sulfonic acid sodium salt (OSA), adjusted to 
pH=3.6) using a Bio-Gen PRO200 homogenizer (PRO Scientific Inc., Oxford, CT, USA). Thereupon, 450 µl homogenate 
was transferred onto a 3000 Da Amicon® Ultra 0.5 Centrifugal Filter (Millipore, Ireland) that had been pre-washed (2x) 
using 450 µl sample buffer (centrifugation: 14000 x g, 25 min, 4°C). The Amicon® filter loaded with homogenate was 
centrifuged (14000 x g, 40 min, 4°C). Per region per mouse, 5 µl of the resulting filtrate was simultaneously injected by 
an Alexys
TM
 AS 100 automatic sample injector onto two parallel ALF-125 columns. 
 
2.5. RP-HPLC 
Noradrenergic (NA, adrenalin and MHPG), dopaminergic (DA, DOPAC and HVA) and serotonergic compounds (TRP, 5-
HT and 5-HIAA) were simultaneously quantified in one run using an optimized RP-HPLC set-up with ion-pairing (OSA) 
and amperometric electrochemical detection, as published before (Dekker et al., 2015a; Van Dam et al., 2014). In 
summary, we used an Alexys
TM
 Dual Monoamines Analyzer (Antec Leyden BV, Zoeterwoude, The Netherlands), 
including two LC 110 pumps for a constant flow rate (40 µl/min), two parallel microbore ALF-125 columns (250 mm x 1 
mm, 3 µm particle size, 36°C) with a porous C18 silica stationary phase for separation of the compounds and two 
Decade II electrochemical amperometric detectors with VT03 electrochemical flow cells containing an In Situ Ag/AgCl 
reference electrode (ISAAC) at 670 mV and a 0.7 mm glassy carbon working electrode. RP-HPLC runs were conducted 
per brain region and compounds were analyzed in duplicate (output ranges resp. 1 nA and 500 pA). The mobile phase 
consisted of the aforementioned sample buffer with 13% methanol as organic modifier. Dihydroxybenzylamine 
hydrochloride (DHBA) and 5-hydroxy-N-methyl tryptamine oxalate (5-HMT) were used as internal standards. 
Chromatograph analyses were performed with Clarity
TM
 software (DataApex Ltd., Prague, Czech Republic).  
 
2.6. Statistics 
Histograms and Shapiro-Wilk tests (P<0.05) demonstrated that the monoamines and metabolites did not have a 
normal distribution overall. Accordingly, non-parametric tests were selected: Mann Whitney U tests were used to 
compare all monoaminergic data between Dp1Tyb and WTDp1Tyb littermates, whereas Kruskal-Wallis with post-hoc 
Mann Whitney U tests were applied to compare the young Ts65Dn, young WTTs65Dn, aged Ts65Dn and aged WTTs65Dn 
groups. To account for multiple comparisons we corrected the P-values using the Benjamini-Hochberg procedure with 
a False Discovery Rate of 0.05 given the exploratory and hypothesis-generating nature of this study. Only the 
corrected P-values smaller than 0.05 (i.e. regarded significant) are reported in Tables 2-4. Statistical analyses were 
performed using IBM SPSS Statistics version 23.0 and Microsoft Office Excel 2010.  
 
 
3. Results 
 
Each monoaminergic compound was detected and quantified in all ten brain regions. Based on these concentrations, 
five accompanying ratios were calculated: MHPG/NA (reflecting noradrenergic metabolism), DOPAC/DA and HVA/DA 
(reflecting dopaminergic catabolism), 5-HIAA/5-HT (reflecting serotonergic catabolism) and, finally, HVA/5-HIAA 
(indicating the effect of serotonergic inhibition on dopaminergic neurotransmission). In the supplementary material 
(S1-S6), the concentrations and ratios for each brain region are provided per experimental group (median and 
quartiles, including the number of samples in which a specific compound was detected). All compounds and ratios 
were compared between young Ts65Dn vs. young WTTs65Dn (Table 2), aged Ts65Dn vs. aged WTTs65Dn (Table 3), aged 
Ts65Dn vs. young Ts65Dn (Table 4), aged WTTs65Dn vs. young WTTs65Dn (Table 5), and young Dp1Tyb vs. young WTDp1Tyb 
mice. Since the Ts65Dn and Dp1Tyb mouse models have different genetic backgrounds and were bred and housed in 
two different institutes, these DS models are not compared with each other, but only to their age-matched WT 
littermates (same background, same conditions). Significant P-values of the individual group comparisons are 
provided in Tables 2 – 4.  
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Table 2: young Ts65Dn vs. young WTTs65Dn mice (aneuploidy effect) 
 
 (nor)adrenergic system dopaminergic system serotonergic system 
 NA A MHPG 
MHPG 
/NA 
DA DOPAC HVA 
DOPAC 
/DA 
HVA 
/DA 
TRP 5-HT 5-HIAA 
5HIAA 
/5HT 
HVA 
/5HIAA 
Frontal cortex - - - - - - - - - - - - - - 
Temporal cortex - - - - - - - - - - - - - - 
Parietal cortex - - - - - - - - - - - - - - 
Occipital cortex - - - - - - - - - - - ↓ 0.006 - - 
Hippocampus - - -  - - - - - - ↓ 0.024 ↓ 0.024 - - 
Striatum - - - - - - - - - - - - - - 
(Hypo)thalamus - - - - ↓ 0.044 ↓ 0.024 - - - - - - - - 
Brainstem - - - - - - - - - - - - - - 
Cerebellum - - - - - - - - - - - - - - 
Olfactory bulb - - ↑ 0.015 ↑ 0.040 - - - - - - - - - - 
Summary - - ↑ ↑ ↓ ↓ - - - - ↓ ↓↓ - - 
 
Red boxes indicate a significant increase, and green boxes depict a significant decrease for a compound or ratio in young Ts65Dn vs. young WTTs65Dn mice. The summary row 
indicates the consequent overall increase (red) or decrease (green). 5-HIAA, 5-hydroxyindoleacetic acid; 5-HT, serotonin; A, adrenaline; DA, dopamine; DOPAC, 3-4-
dihydroxyphenylacetic acid; HVA, homovanillic acid; MHPG, 3-methoxy-4-hydroxyphenylglycol; NA, noradrenaline. 
 
Table 3: aged Ts65Dn vs. aged WTTs65Dn mice (aneuploidy effect) 
 
 (nor)adrenergic system dopaminergic system serotonergic system 
 NA A MHPG 
MHPG 
/NA 
DA DOPAC HVA 
DOPAC 
/DA 
HVA 
/DA 
TRP 5-HT 5-HIAA 
5HIAA 
/5HT 
HVA 
/5HIAA 
Frontal cortex - - ↓ 0.023 - - - - ↓ 0.022 - - - - - - 
Temporal cortex - n.d. - - - - - - ↑ 0.043 - - - -  
Parietal cortex - - - - - - - ↓ 0.035 - - -  - - 
Occipital cortex - - - - - - - - - - - - - - 
Hippocampus - - - - - - - - - - - - - - 
Striatum - - - - - - - - - - - - - - 
(Hypo)thalamus - - - - - - - - - - - - - - 
Brainstem - - - - - - - - - - - - - - 
Cerebellum - - - - - - - ↓ 0.034 - - - - - - 
Olfactory bulb - - - - - - - - - - - - - - 
Summary - - ↓ - - - - ↓↓↓ ↑ - - - - - 
 
Red boxes indicate a significant increase, and green boxes depict a significant decrease for a compound or ratio in aged Ts65Dn vs. aged WTTs65Dn mice. The summary row indicates 
the consequent overall increase (red) or decrease (green). 5-HIAA, 5-hydroxyindoleacetic acid; 5-HT, serotonin; A, adrenaline; DA, dopamine; DOPAC, 3-4-dihydroxyphenylacetic 
acid; HVA, homovanillic acid; MHPG, 3-methoxy-4-hydroxyphenylglycol; NA, noradrenaline; n.d., not detectable. 
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Table 4: aged Ts65Dn vs. young Ts65Dn mice (aging effect) 
 
 (nor)adrenergic system dopaminergic system serotonergic system 
 NA A MHPG 
MHPG 
/NA 
DA DOPAC HVA 
DOPAC 
/DA 
HVA 
/DA 
TRP 5-HT 5-HIAA 
5HIAA 
/5HT 
HVA 
/5HIAA 
Frontal cortex - ↓ 0.017 ↓ 0.031 - - - - - - - - - - - 
Temporal cortex - ↑ 0.003 - - ↑ 0.012 ↑ 0.035 - - ↓ 0.005 - - ↑ 0.000 ↑ 0.003 - 
Parietal cortex - ↓ 0.029 ↓ 0.002 ↓ 0.001 - - - - - - - ↑ 0.004 ↑ 0.047 - 
Occipital cortex - - - - - - - - - - - - - - 
Hippocampus - ↓ 0.039 - - - - ↓ 0.043 - - - - - - - 
Striatum ↑ 0.004 - - ↓ 0.019 ↓ 0.020 - ↓ 0.001 - - - ↑ 0.005 - ↓ 0.015 ↓ 0.007 
(Hypo)thalamus - ↓ 0.039 - - - - - - - - - - - ↓ 0.012 
Brainstem - - - - - - - - - - - - - - 
Cerebellum - - - - - ↑ 0.000 - ↑ 0.000 - - - - - - 
Olfactory bulb - - ↑ 0.019 - - - - - - - - - - - 
Summary ↑ 
↓↓↓
↓↑ 
↓↓↑ ↓↓ ↓↑ ↑↑ ↓↓ ↑ ↓ - ↑ ↑↑ ↓↑↑ ↓↓ 
 
Red boxes indicate a significant increase, and green boxes depict a significant decrease for a compound or ratio in aged Ts65Dn vs. young Ts65Dn mice. The summary row indicates 
the consequent overall increase (red) or decrease (green). The yellow boxes indicate that the direction of the change differed between the different regions: the arrows illustrate 
whether the direction of change is ex aequo (e.g. ↓↑) or inclines towards an increase (e.g. ↓↑↑) or decrease (e.g. ↓↓↑). 5-HIAA, 5-hydroxyindoleacetic acid; 5-HT, serotonin; 
A, adrenaline; DA, dopamine; DOPAC, 3-4-dihydroxyphenylacetic acid; HVA, homovanillic acid; MHPG, 3-methoxy-4-hydroxyphenylglycol; NA, noradrenaline. 
 
Table 5: aged WTTs65Dn vs. young WTTs65Dn mice (aging effect) 
 
 (nor)adrenergic system dopaminergic system serotonergic system 
 NA A MHPG 
MHPG 
/NA 
DA DOPAC HVA 
DOPAC 
/DA 
HVA 
/DA 
TRP 5-HT 5-HIAA 
5HIAA 
/5HT 
HVA 
/5HIAA 
Frontal cortex - ↓ 0.000 - - - - - - - - - ↑ 0.009 ↑ 0.000 - 
Temporal cortex - n.d. - ↑ 0.013 ↑ 0.030 - - ↓ 0.013 ↓ 0.000 ↑ 0.000 - ↑ 0.000 - ↓ 0.000 
Parietal cortex - ↓ 0.000 ↓ 0.000 ↓ 0.000 - - - ↑ 0.011 - - - - ↑ 0.008 - 
Occipital cortex - ↓ 0.000 ↓ 0.001 ↓ 0.000 - - ↓ 0.010 - ↓ 0.001 - - - - ↓ 0.010 
Hippocampus - - - - - - - - ↓ 0.030 - - - - - 
Striatum ↑ 0.014 - - ↓ 0.007 ↓ 0.004 ↓ 0.045 ↓ 0.003 - - - ↑ 0.001 - ↓ 0.002 ↓ 0.005 
(Hypo)thalamus - ↓ 0.001 - - - - ↓ 0.002 - - - - - - ↓ 0.000 
Brainstem - - ↑ 0.007 ↑ 0.001 - - - - - - - - - - 
Cerebellum - - - - - ↑ 0.000 - ↑ 0.000 ↑ 0.017 - - ↑ 0.001 - - 
Olfactory bulb - - ↑ 0.000 ↑ 0.000 - ↑ 0.047 - ↑ 0.012 - ↑ 0.000 - - - - 
Summary ↑ 
↓↓ 
↓↓ 
↓↓ 
↑↑ 
↓↓↓
↑↑↑ 
↓↑ ↓↑↑ ↓↓↓ 
↓↑ 
↑↑ 
↓↓ 
↓↑ 
↑↑ ↑ ↑↑↑ ↓↑↑ 
↓↓ 
↓↓ 
 
Red boxes indicate a significant increase, and green boxes depict a significant decrease for a compound or ratio in aged WTTs65Dn vs. young WTTs65Dn mice. The summary row 
indicates the consequent overall increase (red) or decrease (green). The yellow boxes indicate that the direction of the change differed between the different regions: the arrows 
illustrate whether the direction of change is ex aequo (e.g. ↓↑) or inclines towards an increase (e.g. ↓↑↑) or decrease (e.g. ↓↓↑). 5-HIAA, 5-hydroxyindoleacetic acid; 5-HT, 
serotonin; A, adrenaline; DA, dopamine; DOPAC, 3-4-dihydroxyphenylacetic acid; HVA, homovanillic acid; MHPG, 3-methoxy-4-hydroxyphenylglycol; NA, noradrenaline; n.d., not 
detectable
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3.1. Effect of aneuploidy  
3.1.1. Ts65Dn vs. WTTs65Dn mice 
To determine the effect of the aneuploidy on the monoamine neurotransmitters and their metabolites, we compared 
Ts65Dn mice with their WTTs65Dn littermates. First of all, we compared the young animals (Table 2): MHPG and the 
accompanying MHPG/NA ratio in the olfactory bulb were significantly higher in young Ts65Dn than in young WTTs65Dn 
mice. No other significant changes in the (nor)adrenergic system were found. Concerning the dopaminergic system, 
DA and DOPAC were significantly lower in the (hypo)thalamus of Ts65Dn compared to WTTs65Dn mice, but not in other 
regions. With respect to the serotonergic compounds, decreased levels were observed for 5-HIAA and 5-HT in the 
hippocampus, and 5-HIAA in the occipital cortex of young Ts65Dn compared to young WTTs65Dn mice. 
Secondly, we compared the aged Ts65Dn mice with their aged WTTs65Dn littermates (Table 3). Apart from a 
significant reduction of MHPG in the frontal cortex of Ts65Dn mice, no other significant changes were observed for 
the (nor)adrenergic system in any of the brain regions. Although DA, DOPAC and HVA did not differ significantly 
between the groups, the subsequent ratios turned out to be significantly altered: the DOPAC/DA ratio was lower in 
the frontal cortex, parietal cortex, and cerebellum of Ts65Dn mice (indicating reduced DA catabolism), while the ratio 
HVA/DA in the temporal cortex was increased (indicating increased DA metabolization) in aged Ts65Dn compared to 
aged WTTs65Dn mice. No differences were found in the serotonergic system. 
  
3.1.2. Young Dp1Tyb vs. young WTDp1Tyb mice 
In addition to the Ts65Dn mouse model, we also assessed the monoaminergic profile of young Dp1Tyb mice in 
comparison with their WTDp1Tyb littermates: only the NA concentration in the occipital cortex was significantly 
increased in Dp1Tyb mice compared to WTDp1Tyb (P=0.047), while none of the other monoamines, metabolites or 
ratios were significantly altered between both groups. 
 
3.2. Effect of aging  
3.2.1. Aged Ts65Dn vs. young Ts65Dn mice 
To study the effect of aging in Ts65Dn mice, we compared two age groups: Table 4 depicts the significant differences 
between aged Ts65Dn (~12-13 months) and their younger counterparts (~3-5.5 months). To start with the 
noradrenergic system, NA concentrations only differed in the striatum, but not in other regions. Adrenaline, in 
contrast, was substantially affected by aging: significantly lower levels were found in the frontal cortex, parietal 
cortex, hippocampus and (hypo)thalamus, and higher levels in the temporal cortex. Similarly, MHPG was reduced in 
the frontal and parietal cortex, but was elevated in the olfactory bulb. Consequently, the ratio MHPG/NA in the 
parietal cortex and the striatum was decreased in aged compared to young Ts65Dn mice. Overall, adrenaline, MHPG 
and the MHPG/NA ratio were predominantly reduced with aging. 
 In contrast to these results, the changes in the dopaminergic system are less consistent: DA was increased in 
the temporal cortex, but decreased in the striatum of aged vs. young Ts65Dn mice. DOPAC was significantly higher in 
the temporal cortex and cerebellum, while lower HVA concentrations were found in the hippocampus and striatum. 
The resulting DOPAC/DA and HVA/DA ratios were not altered for the different brain regions, apart from an increased 
DOPAC/DA ratio in the cerebellum and a decreased HVA/DA ratio in the temporal cortex.  
Concerning the serotonergic system, 5-HIAA and the 5-HIAA/5-HT ratio were increased in the temporal and 
parietal cortex, pointing at increased serotonergic turnover. In the striatum, 5-HT was increased and the ratio 5-
HIAA/5HT reduced, indicating reduced serotonergic catabolism. Finally, the inhibitory effect of the serotonergic 
system on the dopaminergic system is reflected by the HVA/5-HIAA ratio, which turned out to be significantly lower in 
the striatum and the (hypo)thalamus of aged Ts65Dn mice compared to their younger counterparts.  
 
3.2.2. Aged WTTs65Dn vs. young WTTs65Dn mice 
To evaluate whether the observed changes in aged Ts65Dn vs. young Ts65Dn mice are specific for this model, i.e. 
relate to the triplicated genes or to aging in general, we also compared aged WTTs65Dn mice (~12-13 months) vs. young 
(~3-5.5 months) animals (Table 5). In the (nor)adrenergic system, striatal NA concentrations were higher in aged than 
in young WTTs65Dn mice, resembling the observed increase in the striatum of Ts65Dn mice. Furthermore, adrenaline 
was lower in the frontal cortex, parietal cortex, occipital cortex and (hypo)thalamus of aged WTTs65Dn mice than in their 
younger counterparts, which again (largely) resembles the aforementioned findings in the Ts65Dn model. In the aged 
animals, MHPG levels were significantly reduced in cortical regions (parietal and occipital cortex), but increased in 
brainstem and olfactory bulb. Accordingly, the ratio MHPG/NA decreased in parietal and occipital cortex, as well as in 
the striatum, and increased in the temporal cortex, brainstem and olfactory bulb.  
 In accordance with the Ts65Dn results, DA levels were significantly higher in the temporal cortex and lower in 
the striatum of aged vs. young WTTs65Dn mice. DOPAC and HVA were both decreased in the striatum as well. In 
addition, aged WTTs65Dn animals showed increased DOPAC levels in the cerebellum and olfactory bulb, and reduced 
HVA concentrations in the occipital cortex and (hypo)thalamus, compared to their younger counterparts. Concerning 
the ratios, DOPAC/DA was predominantly increased (parietal cortex, cerebellum and olfactory bulb, but decreased in 
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temporal cortex), while the ratio HVA/DA was mainly decreased (temporal cortex, occipital cortex and hippocampus, 
but increased in cerebellum).  
 Finally, an overall increase of serotonergic compounds became apparent when comparing aged vs. young 
WTTs65Dn mice. Significant increases were found for tryptophan in the temporal cortex and olfactory bulb, 5-HT in the 
striatum, 5-HIAA in the frontal cortex, temporal cortex and cerebellum and the ratio 5-HIAA/5-HT in the frontal cortex 
and parietal cortex. In contrast, the ratio 5-HIAA/5HT was decreased in the striatum. As in Ts65Dn mice, the ratio 
HVA/5-HIAA was generally reduced in aged WTTs65Dn mice, indicating enhanced serotonergic inhibition on the 
dopaminergic system. 
 
 
4. Discussion 
 
Using a previously optimized and validated RP-HPLC methodology (Van Dam et al., 2014), we detected noradrenergic 
(NA, adrenaline and MHPG), dopaminergic (DA, DOPAC and HVA) and serotonergic (TRP, 5-HT and 5-HIAA) 
compounds in ten regionally dissected brain regions to establish the monoaminergic profiles of Dp1Tyb and Ts65Dn 
mice and their WT littermates. First of all, we studied the effect of aneuploidy in both models. Comparing young 
Dp1Tyb with young WTDp1Tyb showed that only occipital NA levels differed significantly, suggesting that the additional 
genes in Dp1Tyb mice hardly affected monoamine concentrations at this age. Similarly, Tables 2 and 3 depict the 
comparisons between Ts65Dn mice and WTTs65Dn littermates, and do not show generalized monoaminergic 
dysregulation either, even though a few more changes were regarded significant than in the Dp1Tyb mouse model. 
Accordingly, the genetic overload in these DS mouse models barely affected the absolute monoaminergic 
concentrations at the analyzed ages. Secondly, we studied the effect of aging within Ts65Dn and WTTs65Dn mice 
comparing aged (~12-13 months) vs. young animals (~3-5.5 months). The overall patterns of monoaminergic 
alterations appeared to be relatively similar in both genotypes, though more observed changes (especially in the 
ratios) were regarded significant for WTTs65Dn mice. Indeed, these overall patterns, rather than the individual 
concentration changes in a specific region, are most relevant in this exploratory study. In the next section, the main 
patterns and changes will be highlighted and discussed. 
    
4.1. Noradrenergic system 
The LC, located in the pons near the fourth ventricle, is the major source of NA in the brain. The ascending 
noradrenergic neurons originating from this small nucleus project to an extensive number of (sub)cortical brain 
regions, including the frontal cortex, hippocampus, striatum, (hypo)thalamus, cerebellum and olfactory bulb, 
mediating, amongst others, arousal, attention and contextual memory. Importantly, LC neurons are the sole source of 
NA for the cortex, hippocampus, cerebellum and most of the thalamus (Aston-Jones and Cohen, 2005; Trillo et al., 
2013; Vermeiren et al., 2016). A loss of LC neurons may thus especially affect these brain areas.  
Previously, such a loss was reported in Ts65Dn mice of 6, 12 and 18 months but not in younger Ts65Dn mice 
(aged 3 and 4 months) compared to age-matched WTTs65Dn mice (Fortress et al., 2015; Lockrow et al., 2011; Salehi et 
al., 2009). Here, we did not observe significant NA concentration changes between Ts65Dn and WTTs65Dn in both age 
groups for the brainstem (including LC) or any of the noradrenergic projection regions (Tables 2 and 3). Indeed, 
immunohistochemical characterization of the catecholaminergic nuclei (anti-tyrosine hydroxylase antibodies) 
previously showed intense staining of the LC in both Ts65Dn and control mice (3 months) without evident differences 
between both groups, indicating that the additional genes in Ts65Dn did not influence the early LC development 
(Megías et al., 1997). This is further supported by human findings: NA levels were not significantly altered in the 
frontal cortex of fetal DS tissue (20 weeks) as compared to age-matched non-DS fetuses (Whittle et al., 2007). 
Similarly, the genetic overload in Dp1Tyb mice does not appear to affect NA levels other than an increase in the 
occipital cortex in comparison with WTDp1Tyb mice – that is the only significant difference in all compounds and regions 
in this strain. Next, comparing trisomic mice with their WT littermates revealed no significant changes in adrenaline, 
whereas MHPG was only altered in the olfactory bulb of young Ts65Dn vs. WTTs65Dn and frontal cortex of aged Ts65Dn 
vs. WTTs65Dn mice. The latter resembles the reduced levels of MHPG, which freely diffuses over the blood-brain barrier, 
in serum of elderly DS individuals as compared to non-DS controls (Dekker et al., 2015a), and may relate to the 
previously reported deficits in (pre)frontal cortex-mediated spatial working memory in Ts65Dn mice aged 9-12 months 
(Dudchenko, 2004; Faizi et al., 2011; Yoon et al., 2008). Nevertheless, it appears that the aneuploidy had a very limited 
effect on the (nor)adrenergic system. 
In contrast, the effect of aging (i.e. comparing aged vs. young animals of the same genotype) is pronounced 
for adrenaline and MHPG, but not for NA. We did not find age-related NA alterations other than the increased NA 
levels in the striatum (Tables 4 and 5). Interestingly, the precursor of NA, that is DA, was decreased in the striatum of 
the aged mice, possibly pointing at an increased turnover of DA into NA (Tables 4 and 5). The virtually unaltered NA 
levels between the young and aged animals possibly relate to enhanced NA synthesis in the remaining noradrenergic 
cells, i.e. a compensatory mechanism (Schapiro et al., 1987). With progressive neuronal loss in the LC during aging 
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(Fortress et al., 2015; Lockrow et al., 2011; Salehi et al., 2009), which is also observed in DS (Mann et al., 1987b; 
Marcyniuk et al., 1988), the increasingly smaller number of remaining cells will not be able to keep noradrenergic 
neurotransmission at level, causing NA concentrations to start decreasing from a certain moment onwards. Indeed, 
Salehi et al. found an age-related decrease in hippocampal NA concentrations, which was only significant for Ts65Dn 
vs. WTTs65Dn at 18 months. Interestingly, immunostaining for the β1-adrenergic receptor, present on postsynaptic 
targets of LC neurons in the hippocampus, revealed an increased size (at 3 and 6 months) and number (at 6 months) 
of immune-reactive cells in Ts65Dn mice compared with age-matched WTTs65Dn mice, pointing at a postsynaptic 
compensation for the age-related decrease in NA levels (Salehi et al., 2009). This may resemble the human situation, 
where significantly reduced NA levels have been reported later in life in several (sub)cortical post-mortem brain 
samples of elderly DS individuals presenting AD neuropathology as compared to controls (Godridge et al., 1987; 
Reynolds and Godridge, 1985; Risser et al., 1997; Yates et al., 1981).  
 Conversely, adrenaline levels appear to be substantially altered over time in both Ts65Dn and WTTs65Dn mice. 
A relatively similar pattern was observed for both genotypes: older animals had significantly decreased adrenaline 
levels in cortical regions and (hypo)thalamus (Table 4 and 5). Hippocampal adrenaline was also reduced in aged 
Ts65Dn. Adrenaline is formed by methylation of NA by the rate-limiting enzyme phenylethanolamine N-
methyltransferase (PNMT, Fig.1). The reduced adrenaline levels are not likely due to reduced NA levels, given the fact 
that NA levels were unaltered. Instead, lower adrenaline levels may be due to a decrease in the amount or activity of 
PNMT enzyme. Burke and co-workers, for instance, described a strong reduction of enzymatic activity due to lower 
amounts of PNMT enzymes in human AD brain tissue as compared to controls (Burke et al., 1987). Since the current 
study methodology did not enable enzymatic measurements (the small tissue samples were entirely used for RP-HPLC 
analyses), future studies need to elucidate whether PNMT plays a role in the adrenergic changes in these mice. 
 MHPG levels were also affected by aging: reduced adrenaline levels in the frontal and parietal cortex of aged 
Ts65Dn mice, and parietal and occipital cortex of aged WTTs65Dn mice likely resulted in the decreased MHPG levels in 
these regions. Whereas MHPG and the MHPG/NA ratio generally decreased with aging in Ts65Dn, the pattern for 
WTTs65Dn mice was more diffuse. NA and adrenaline are converted into MHPG through the enzymes monoamine 
oxidase (MAO, Fig.1) and catechol-O-methyltransferase (COMT, Fig.1). Previously, MAO activity in platelets of DS 
individuals was found to be reduced (Benson and Southgate, 1970; Fowler et al., 1981) or unaltered (Lott et al., 1972), 
whereas COMT activity was higher (Gustavson et al., 1973) or unaltered (Brahe et al., 1985) in DS erythrocytes. The 
COMT enzyme is a methyl transferase, using the methyl group of S-adenosylmethionine (SAM). The levels of the 
methyl donor SAM are reduced in DS (Dekker et al., 2014), suggesting that COMT activity might be reduced in DS as 
well. Nevertheless, it remains to be elucidated whether the amount or activity of MAO and COMT change over time in 
these mice.  
Taken together, the (nor)adrenergic system was not substantially affected by the aneuploidy in Ts65Dn or 
Dp1Tyb mice. However, aging revealed strong alterations in multiple brain regions. Since LC degeneration and altered 
(nor)adrenergic neurotransmission are implicated in DS and AD, others have studied the effect of (nor)adrenergic 
agonists in (aged) Ts65Dn mice as potential therapeutic strategies (Phillips et al., 2016). Faizi and colleagues, for 
instance, reported reproducible learning and memory deficits in Ts65Dn mice of 9-12 months of age that could be 
restored by administering the β1-adrenergic receptor partial agonist xamoterol, thus suggesting that such cognitive 
deficits are (in part) mediated by the (nor)adrenergic system (Faizi et al., 2011). Similarly, xamoterol and the NA-
prodrug L-DOPS reversed contextual learning impairment in 6-month-old Ts65Dn mice (Salehi et al., 2009). Moreover, 
the long-acting β2-adrenergic receptor agonist formoterol significantly improved cognitive capacities, synaptic density 
and complexity of the dendritic tree of new dentate granule cells in the hippocampus of Ts65Dn mice (5-6 months) 
(Dang et al., 2014). More recently, Fortress and colleagues demonstrated LC degeneration in 12-month-old Ts65Dn 
mice, and found that selective stimulation of the remaining noradrenergic LC neurons using designer receptors 
exclusively activated by designer drugs (DREADDs) restored memory function (Fortress et al., 2015). 
In the context of the high risk for AD in DS, it is important to note that the amyloid precursor protein (APP) 
gene located on HSA21 is also triplicated in Ts65Dn mice, but that the APP cleavage product amyloid-beta (Aβ) does 
not accumulate into plaques in Ts65Dn mice like in the human condition (Gardiner, 2015; Reeves et al., 1995). 
Consequently, Ts65Dn is primarily a model of the developmental trisomy 21-related deficits in DS and can be used to 
study the effect of APP overexpression, but not Aβ accumulation, with aging. Interestingly, Salehi and colleagues 
found that the loss of LC neurons was eliminated by deleting the third copy of the APP gene in Ts65Dn mice, thus 
indicating that triplicated APP plays an essential role in LC degeneration (Salehi et al., 2009). Indeed, a comparable cell 
loss of approximately 60% was found in post-mortem LC samples from elderly DS (57-59 years) and AD patients (61-82 
years) in the general population compared to healthy controls (60-76 years) (German et al., 1992). Importantly, in 
both AD and older DS samples, neuronal loss mainly affected the neurons projecting to the cortex, while the non-
cortical projecting cells were spared (German et al., 1992; Marcyniuk et al., 1988). Similarly, LC neuronal loss in 
Ts65Dn mice at 12 months was mainly restricted to the rostral neurons projecting to the forebrain and hippocampus, 
while the caudal regions were spared (Lockrow et al., 2011). That might explain the discrepancy between our finding 
of decreased cortical MHPG levels and the increased MHPG concentrations in the brainstem with aging. Cautious 
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interpretation of the results is warranted in relation to findings in aged post-mortem DS samples: virtually all DS 
individuals have omnipresent AD-pathology (i.e. Aβ plaques and tau tangles) in their brain from the age of 40 years 
onwards (Mann, 1988), complicating the comparison between findings in DS and Ts65Dn mice that do not model 
human AD neuropathology in DS. 
Interestingly, LC degeneration does not only affect noradrenergic neurotransmission, but also impacts 
cholinergic signaling (Lockrow et al., 2011). Basal forebrain cholinergic neurons innervate the amygdala, hippocampus 
and neocortex and are strongly implicated in attention and memory processes. A significant loss of cholinergic cells 
has been found in AD and DS (Casanova et al., 1985; Mann et al., 1985; Mufson et al., 2003) and in Ts65Dn mice by 12 
months of age (Cooper et al., 2001). LC degeneration in Ts65Dn mice appears to precede the onset of cholinergic 
degeneration (Phillips et al., 2016). Indeed, Lockrow and colleagues demonstrated that neurotoxin-induced NA 
depletion resulted in accelerated cholinergic degeneration in Ts65Dn mice, but not in WTTs65Dn mice. Learning and 
memory deficits were aggravated in Ts65Dn mice as well (Lockrow et al., 2011). In the current study, we report an 
overall decrease of adrenaline, MHPG and the MHPG/NA ratio with aging in Ts65Dn mice, which may possibly 
contribute to cholinergic pathology in this mouse model. Future studies should consider studying monoaminergic 
alterations in relation to cholinergic deficits.  
 In conclusion, the (nor)adrenergic system was mainly affected by aging rather than by aneuploidy. Comparing 
aged vs. young animals revealed altered patterns across multiple brain regions. In particular, adrenaline and MHPG 
differed in most cortical regions as well as in a few subcortical structures. In Ts65Dn an overall decrease of adrenaline, 
MHPG and the MHPG/NA ratio became apparent with aging. In WTTs65Dn mice, adrenaline decreased with aging as 
well, while the directions of change for MHPG and MHPG/NA were less straightforward. 
 
4.2. Dopaminergic system 
DA, derived from L-tyrosine (Fig.1), is mainly produced by the substantia nigra (SN) and ventral tegmental area (VTA) 
located in the mesencephalon. The SN primarily projects to the striatum (hence referred to as the nigrostriatal 
pathway), whereas the VTA projects to the limbic (mesolimbic pathway) and cortical areas (mesocortical pathway). DA 
is involved in regulating motor activity, emotions, reward and has been associated with cognition (Lanari et al., 2006; 
Nieoullon, 2002; Trillo et al., 2013).  
 Studying the effect of aneuploidy on the dopaminergic system showed that the levels of DA, DOPAC and HVA 
are virtually unaltered, apart from decreased DA and DOPAC levels in the (hypo)thalamus of young Ts65Dn vs. 
WTTs65Dn mice. Indeed, immunohistochemical staining of the dopaminergic neurons (anti-tyrosine hydroxylase 
antibodies) in the SN and VTA of 3-month-old Ts65Dn mice and WTTs65Dn mice revealed similar reaction intensities in 
both genotypes. The unaltered morphology and number of reactive cells between Ts65Dn and WTTs65Dn led the 
authors to conclude that the triplicated genes in Ts65Dn do not affect the development of dopaminergic nuclei 
(Megías et al., 1997). In young Ts65Dn mice, we found reduced DA levels in the (hypo)thalamus. In the human 
situation, levels of DA and the DA receptor 1-containing complex were significantly lower in the frontal cortex of DS 
fetuses than in age-matched control fetuses (Keihan Falsafi et al., 2016; Whittle et al., 2007). Furthermore, the lack of 
significant alterations between the older Ts65Dn and WTTs65Dn mice resembles the lack of significant changes in 
multiple post-mortem brain samples of DS individuals vs. controls (Godridge et al., 1987). 
 In contrast to the relatively consistent age-related patterns of change in the (nor)adrenergic (section 4.1) and 
serotonergic systems (section 4.3), the results for the dopaminergic system are less consistent over the months for 
the different compounds/regions. In the human situation, Mann and colleagues reported neuronal loss in the VTA, but 
not in the SN of aged DS (51-65 years) and AD patients (53-89 years) (Mann et al., 1987a). Indeed, comparison of older 
and younger DS samples revealed no significant cell loss or reduced nucleolar volume in the SN over time (Mann et al., 
1987b). In Ts65Dn mice of 3 months, neuronal loss was absent (Megías et al., 1997), but whether this is true for aged 
Ts65Dn mice remains unclear. With aging, this study showed that DA increased in the temporal cortex, but decreased 
in the striatum for aged vs. young Ts65Dn mice, as well as for aged vs. young WTTs65Dn mice. In mice, striatal neurons 
receive input from both the SN and VTA (Zeiss, 2005). The finding that DOPAC is increased in various regions, while 
HVA is decreased may relate to changes in MAO or COMT activity (Fig. 1). COMT transfers a methyl group of SAM to 
DOPAC (3-O-methylation) resulting in HVA (Meiser et al., 2013). As described before, the levels of the methyl donor 
SAM are reduced in DS (Dekker et al., 2014), possibly affecting DOPAC methylation and thus HVA levels.  
 In short, the dopaminergic system was barely affected by the triplicated HSA21-homologous genes in Ts65Dn 
or Dp1Tyb mice compared to their WT littermates. Aging resulted in altered DA, DOPAC and HVA levels, but further 
studies are required to mechanistically demonstrate the cause of these alterations. 
 
4.3. Serotonergic system 
The indolamine 5-HT, derived from L-tryptophan (Fig. 1), is produced in various cell groups in the medulla, pons and 
mesencephalon. The majority of ascending serotonergic neurons arise from the dorsal and median raphe nuclei. In 
particular, the dorsal raphe nuclei project to the cortex and striatum, while the median raphe nuclei target the cortex, 
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hippocampus and hypothalamus (Trillo et al., 2013). The main role of the serotonergic system is (behavioral) 
inhibition, and regulation of mood and aggression, for instance (Lanctôt et al., 2001). 
 Here, we did not find widespread serotonergic changes between Ts65Dn and WTTs65Dn mice. This is in 
accordance with the conclusion of Megías et al. that the development of the serotonergic system is not evidently 
influenced by the triplicated genes in Ts65Dn mice. Indeed, their immunohistochemical results demonstrated a similar 
distribution of serotonin-immunoreactive cells (anti-serotonin antibodies) in the medial and dorsal raphe nuclei of 
Ts65Dn and WTTs65Dn mice at 3 months of age (Megías et al., 1997). 5-HT has been implicated in the impaired 
hippocampal neurogenesis and dendritic hypotrophy in Ts65Dn mice. Ts65Dn mice, similar to DS individuals, have a 
smaller hippocampus indeed. Prenatal and neonatal treatment with the selective serotonin reuptake inhibitor 
fluoxetine was found to normalize hippocampal neurogenesis and restore dendritic architecture, hippocampal 
cellularity and memory functions, even 1.5-3 months after treatment cessation (reviewed in: Stagni et al., 2015). 
Although we do not see many serotonergic changes between both genotypes, we did find significantly reduced 5-HT 
and 5-HIAA levels in the hippocampus of young Ts65Dn compared to young WTTs65Dn mice.  
 Whether these findings reflect the human situation remains unclear due to a lack of (post-mortem) studies in 
young DS individuals. Reduced 5-HT and 5-HIAA levels have, indeed, been reported in post-mortem DS hippocampus 
samples (Godridge et al., 1987; Reynolds and Godridge, 1985). Other studies confirmed the pattern of lower 5-HT and 
5-HIAA concentrations in DS (Risser et al., 1997; Seidl et al., 1999; Whittle et al., 2007; Yates et al., 1986). These 
human post-mortem studies were mainly performed on samples of elderly DS individuals presenting AD 
neuropathology. For instance, Yates et al. studied six DS brains over 50 years of age with numerous plaques and 
tangles in the cortex and reported significantly decreased 5-HT levels in amygdala, caudate nucleus (part of striatum) 
and cingulate cortex, but no such change was found in a 27-year-old DS case without AD pathology (Yates et al., 
1986). Considering fetal samples, however, Whittle et al. found reduced 5-HT and 5-HIAA in the frontal cortex of fetal 
DS tissue as compared to age-matched control aborted fetuses (Whittle et al., 2007), suggesting that this reduction is 
not related to the AD pathology, but to the trisomy 21 itself. To which extent the murine findings thus resemble the 
human situation is questionable given the fact that Aβ does not accumulate into plaques in these mice, and 
comparison of aged Ts65Dn with aged WTTs65Dn did not yield significant alterations in any serotonergic compound or 
region.  
 Studying the effect of aging within each genotype revealed a more pronounced pattern: an overall increase of 
serotonergic compounds with aging. This is in remarkable contrast with the aforementioned reduced serotonergic 
levels in the elderly DS brain samples. Indeed, comparison of older DS brains (with AD pathology) with young DS 
brains (without/minimal AD pathology) revealed a significant decrease in the number of cells and the nucleolar 
volume with aging (Mann et al., 1987b). Neuronal loss has been reported in the dorsal tegmental nucleus of the raphe 
nuclei in six DS patients over 50 years, as well as in AD patients in the general population (Mann et al., 1985). The 
activity of the tryptophan hydroxylase enzyme (Fig. 1), key to 5-HT biosynthesis, is reduced in AD as well (Trillo et al., 
2013), but whether this is also true for DS and Ts65Dn is unclear. The link between AD pathology and 5-HT levels is 
further supported by the finding that the increased levels of APP-derived βCTF peptide could be normalized in adult 
Ts65Dn mice through fluoxetine treatment (Stagni et al., 2015). Therefore, the underlying mechanism of serotonergic 
increase with aging in these mice should be studied more extensively. 
 
4.4. Future implications 
Cautious interpretation of the results is required, because the underlying causes for (the lack of) 
monoaminergic alterations remain to be elucidated. The virtually unaltered NA levels and the likely presence of a 
compensatory mechanism, for instance, illustrate the necessity to study monoaminergic alterations over a longer 
period of time. Therefore, we propose that future studies should evaluate mice in a larger number of age groups, for 
instance at 3, 6, 9, 12, 15, 18 and 21 months. Immunohistochemical staining of (nor)adrenergic, dopaminergic and 
serotonergic neurons, and measurements of the amount and activity of key enzymes like PNMT, MAO and COMT 
(Fig.1) in mice of different ages would be a valuable addition to understand the age-related changes. Despite the fact 
that the age ranges of the young Ts65Dn and Dp1Tyb mice in the current study slightly overlapped, the young Ts65Dn 
mice were, on average, a few weeks older than the Dp1Tyb mice. Although it was not the aim to compare both 
models with each other (different genetic backgrounds and different institutes), it could be considered a limitation of 
this study. Comparative age-matched studies should certainly be considered in the future, providing that the mice are 
bred and housed at the same location. Moreover, the novel Dp1Tyb mouse model has not been fully characterized 
yet. Dp1Tyb mice present congenital heart defects comparable to DS (Lana-Elola et al., 2016). Brain morphology and 
behavioral deficits have not been reported so far, although brain development and cognitive deficits in Dp1Tyb mice 
are expected to resemble those reported in the essentially similar Dp(16)1Yey mouse model (Goodliffe et al., 2016; Yu 
et al., 2010). Future studies should specifically evaluate the behavioral phenotype (DS-related deficits) of Dp1Tyb mice 
in young, adult and aged life. 
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 Currently, it is complex to evaluate the monoaminergic construct validity of the mouse models in comparison 
with the human situation, because of the lack of comprehensive post-mortem brain studies in DS. The few available 
monoaminergic studies were conducted twenty to forty years ago and have various methodological limitations, 
including (1) long post-mortem delays (PMD), (2) small sample sizes, and (3) absence of DS brains free of extensive AD 
pathology. First, long PMDs over 30 hours, for instance, were not unusual (Godridge et al., 1987; Risser et al., 1997). 
Indeed, PMD is a confounding factor since it may affect the (regional) concentrations of specific monoamines and 
metabolites (Kontur et al., 1994; Van Dam et al., 2014). Therefore, we have submersed the mice in liquid nitrogen 
within minutes to stop further monoaminergic turnover. Secondly, (very) small sample sizes were used, ranging from 
2 to 8 individuals (Godridge et al., 1987; Reynolds and Godridge, 1985; Risser et al., 1997; Yates et al., 1981), thus 
complicating the generalizability of the human results. Thirdly, mainly older DS brains with virtually omnipresent AD-
like neuropathology were studied (Mann, 1988), making it rather complex to disentangle the effects of AD pathology, 
normal aging, and trisomy 21. To establish whether the monoaminergic phenotypes of DS mouse models reflect 
alterations in the human situation, we should study post-mortem human brain samples in greater detail, and thus 
prioritize the collection of these samples through, for instance, multicenter brain bank initiatives. In short, 
monoamine neurotransmitter systems have not been comprehensively studied in the human DS situation, illustrating 
the need to be careful with drawing conclusions at this stage about the monoaminergic construct validity of Ts65Dn 
and Dp1Tyb mouse models. 
 With respect to the high risk for AD in DS, the scientific community is in great need of animal models that 
integrate DS and AD phenotypes, i.e. a model for the neurodevelopmental deficits in DS (such as Ts65Dn) that also 
develops AD pathology and related neurodegeneration over time. Clearly, overexpression of wild-type APP is not 
sufficient for the development of vast AD neuropathology in these mice (Wiseman et al., 2015). Indeed, we studied 
the effect of triplicated genes, including APP, as well as the effect of normal aging in these mice that model DS, but 
not AD. Novel rodent models for AD in DS are being developed, but these are not available yet. Such models would be 
of great value to study monoaminergic changes due to ‘pathologic’ aging. 
  
 
5. Conclusion 
 
To the best of our knowledge, this study is the first to comprehensively quantify monoamine neurotransmitters and 
metabolites in ten regionally dissected brain regions in two DS mouse models in comparison with their WT 
littermates. Monoaminergic concentrations were barely altered by the aneuploidy in young adult Ts65Dn and Dp1Tyb 
mice compared with their WT littermates. Aging to 12-13 months, however, revealed strong alterations in the 
monoaminergic compounds in multiple brain regions in both Ts65Dn and WT mice. Future studies should focus on 
replicating these age-related monoaminergic alterations and elucidate the underlying causes. Post-mortem studies 
with human DS brain samples are necessary to validate the monoaminergic construct validity of the Ts65Dn and 
Dp1Typ mouse models of DS. 
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FIGURE CAPTION 
 
Figure 1: Schematic biosynthesis routes of monoamine neurotransmitters and their main metabolites. 5-HT is 
derived from the amino acid tryptophan, whereas DA (and thus NA and A) are derived from the amino acid tyrosine. 
The molecular structures are provided for the compounds that are quantified in this study through reversed-phase 
high-performance liquid chromatography (RP-HPLC) analyses. Abbreviations: AADC, aromatic amino acid 
decarboxylase; ALDH, aldehyde dehydrogenase; COMT, catechol-O-methyltransferase; DBH, dopamine β-hydroxylase; 
DDC, DOPA decarboxylase; L-DOPA, L-3,4-dihydroxyphenylalanine (levodopa); MAO, monoamine oxidase; PNMT, 
phenylethanolamine N-methyltransferase; TH, tyrosine hydroxylase; TPH, tryptophan hydroxylase. 
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 Monoamine neurotransmitters and metabolites appear to be altered in Down syndrome 
 The monoaminergic brain profile of two Down syndrome mouse models was examined 
 Aneuploidy barely affected monoamines in Ts65Dn and Dp1Tyb mice vs. wild-type mice 
 Aging to 12-13 months showed strong monoaminergic changes in the Ts65Dn mouse model 
 Construct validity needs to be established by similar human post-mortem studies 
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